Haleon’s business strategy in 2026 combines the Win as One programme, scientific innovation, productivity and disciplined investment. This article relies on Haleon’s audited 2025 Annual Report and distinguishes reported and non-IFRS measures.
Win as One and Brand-Led Growth
Consumer health rather than prescription pharmaceuticals
Haleon is a standalone consumer healthcare company with brands spanning oral health, vitamins and supplements, pain relief, respiratory health, digestive health and therapeutic skin health. Its business model differs from prescription pharmaceutical development: consumers often choose products themselves or with pharmacy advice, while Haleon must establish efficacy, quality, trust and broad availability. The company develops, manufactures and markets products sold through pharmacies, supermarkets, online channels and distributors. Retailers receive their own margins; Haleon does not record the full price paid at checkout as its revenue. Repeat purchase and trusted brands matter, but consumer spending and seasonal illness can change demand.
Win as One strategy
Haleon introduced its Win as One strategy in May 2025, focusing on consistent growth, productivity gains and an agile performance-oriented culture. Management identified operating leverage, cash generation and disciplined capital allocation as drivers of value. The strategy aims to improve category execution and use efficiency savings to invest in brands and innovation. A new operating model was announced in January 2026 to improve accountability and marketing capabilities. Organisational redesign can improve decisions but also creates implementation risk. The strategic test is whether growth and margins improve without undermining scientific standards, customer relationships or workforce effectiveness.
2026 outlook and risks
Haleon’s 2025 Annual Report sets out a 2026 expectation of 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency. These are management expectations, not guaranteed results. Medium-term ambitions include 4% to 6% annual organic revenue growth. Risks include weaker consumer demand, retailer inventory changes, cold and flu incidence, product safety, regulatory requirements, foreign exchange and competition. Investors should track organic versus reported revenue, price versus volume/mix, category market share, operating margins, cash flow and leverage. The business model succeeds when trusted brands generate repeat demand and productivity finances sustainable innovation.
Related Haleon analysis: Business Model | Business Strategy | SWOT | PESTEL
Scientific Innovation and Category Leadership
Six categories and brand architecture
The 2025 Annual Report identifies six categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. Brands include Sensodyne, parodontax, Polident, Centrum, Caltrate, Advil, Panadol, Voltaren, Theraflu, Otrivin, Tums, ENO and Fenistil. Each brand has distinct consumer needs, regulations and channel dynamics. Haleon can share capabilities in science, marketing and distribution, but must adapt claims and formulations by category and geography. Its reported leadership positions in several categories provide scale, not immunity from competitive innovation or consumer trade-down.
Oral Health and repeat consumption
Oral Health was a standout growth category in 2025, with 7.9% organic revenue growth. Brands such as Sensodyne, parodontax and Polident address sensitivity, gum care and denture needs. Unlike episodic respiratory remedies, toothpaste and related oral-care products can generate frequent repeat purchases. Differentiation depends on perceived and demonstrated performance, dentist recommendations, product experience and affordability. Premiumisation can support revenue per unit, but consumers may switch to lower-priced alternatives if budgets tighten. Haleon must continually invest in scientific evidence and brand communication while maintaining reliable retail distribution.
Vitamins and supplements
The vitamins, minerals and supplements category includes brands such as Centrum and Caltrate. Consumer interest in preventive health creates potential demand, but purchase behaviour depends on perceived benefit, affordability and the strength of supporting claims. Regulatory rules for supplements differ by market and from those governing medicines. The company needs disciplined product development and clear communication about appropriate use. A broad range can address different needs but also increase manufacturing and inventory complexity. The commercial challenge is to build trust and repeat purchasing without overstating product benefits or relying solely on marketing claims.
Pain Relief and Respiratory Health
Pain Relief includes brands such as Advil, Panadol and Voltaren, while Respiratory Health includes Theraflu and Otrivin. Demand for pain relief can be recurrent, whereas cough and cold categories fluctuate with seasonal illness. Haleon’s 2025 report identified a weaker cold and flu season as a headwind, estimated at about 40 basis points of full-year organic growth. This is a reminder that even strong brands cannot control the underlying incidence of illness. Forecasting, product availability, regulatory compliance and responsible advertising matter. Promotional spending should be assessed against genuine consumer demand and margin, not only shipment volumes.
Related Haleon analysis: Business Model | Business Strategy | SWOT | PESTEL
Regional Execution and Portfolio Choices
Digestive and skin health
Digestive Health includes brands such as Tums and ENO, while Therapeutic Skin Health and Other includes products for skin-related needs. These categories provide additional consumer occasions and reduce dependence on any single condition. The competitive environment includes established brands, private labels and local products. Consumers may seek quick symptom relief, convenient formats and credible product claims. Haleon needs local market knowledge because formulations, consumer preferences and regulations differ. Portfolio diversification supports resilience only when each category produces acceptable returns after manufacturing, distribution, advertising and research costs.
Regional operating differences
North America recorded negative 0.4% organic revenue growth in 2025, compared with positive 4.7% in EMEA and Latin America and 5.2% in Asia-Pacific. This divergence demonstrates that global consumer healthcare is not one homogeneous market. Distribution, retail inventory, seasonal illness, consumer purchasing power and product mix differ by geography. China is strategically important, and Haleon acquired the remaining stake in its TSKF joint venture during the year. Growth in one region may offset weakness elsewhere, but local performance should be evaluated against category demand and currency translation. Global averages can obscure market-specific challenges.
Portfolio and capital allocation
Haleon completed the final Pfizer shareholding sell-down in March 2025, an ownership milestone rather than product revenue. It acquired the remaining 12% interest in its TSKF joint venture in China, increasing exposure to an important growth market. During 2025 the company returned approximately £1.1 billion to shareholders through dividends and buybacks. Management’s stated medium-term ambition includes leverage around 2.5 times net debt to adjusted EBITDA. Capital allocation must weigh brand investment, bolt-on acquisitions, debt reduction and shareholder distributions. An acquisition creates value only when expected returns justify the price and integration risks.
Related Haleon analysis: Business Model | Business Strategy | SWOT | PESTEL
Productivity, Supply Chain and Operating Leverage
Gross profit and manufacturing economics
Reported gross profit was £7.080 billion in 2025, equivalent to a 64.2% reported gross margin. Adjusted gross profit was £7.193 billion and adjusted gross margin 65.2%. These are not interchangeable measures. Gross profit represents revenue after cost of sales, before marketing, research, distribution and other operating expenses. Haleon sought efficiencies by reducing stock-keeping units, packaging specifications and formulation complexity. Productivity can improve margin and free funds for brand investment, but excessive simplification could weaken consumer choice or service. The economic objective is sustainable margin expansion while maintaining product quality.
Operating profit and earnings quality
Haleon reported statutory operating profit of £2.412 billion in 2025, up 9.3%, and adjusted operating profit of £2.526 billion. The adjusted operating margin was 22.9%, versus a reported margin of 21.9%. Organic operating profit grew 10.5%, reflecting pricing, productivity and investment discipline. These measures differ in treatment of adjustments and exchange rates. A strong underlying profit trend is encouraging, but investors should review the reconciliations rather than assume adjusted and statutory figures are equivalent. The company’s ability to convert revenue into profit depends on cost of goods, marketing efficiency, research and organisational productivity.
Advertising and research investment
Haleon increased advertising and promotional spending by 7.5% at constant currency in 2025, with A&P reaching 20.5% of revenue. Adjusted R&D expenditure increased 7.7% at constant currency. This illustrates a strategic trade-off: productivity savings can fund stronger brands and scientific innovation rather than flow entirely into short-term profit. Marketing can reinforce awareness and repeat purchase, but must be grounded in appropriate claims. R&D can support differentiated products and evidence generation, yet not every innovation succeeds. Investors should evaluate whether higher spending produces category share gains, pricing resilience and long-term cash flow.
Related Haleon analysis: Business Model | Business Strategy | SWOT | PESTEL
Cash Generation and Capital Allocation
Free cash flow and balance sheet
Free cash flow was £1.913 billion in 2025, compared with approximately £1.944 billion in 2024 under Haleon’s definition. Operating cash inflow was £2.634 billion, higher than the previous year’s £2.301 billion. The company reported net debt to adjusted EBITDA of 2.6 times, improved from 2.8 times at the end of 2024. These measures show both cash generation and continuing leverage. Free cash flow is a non-IFRS measure and must be read with its reconciliation. Cash supports product investment, acquisitions, debt management, dividends and share buybacks. Sustainable capital allocation depends on balancing these demands.
Portfolio and capital allocation
Haleon completed the final Pfizer shareholding sell-down in March 2025, an ownership milestone rather than product revenue. It acquired the remaining 12% interest in its TSKF joint venture in China, increasing exposure to an important growth market. During 2025 the company returned approximately £1.1 billion to shareholders through dividends and buybacks. Management’s stated medium-term ambition includes leverage around 2.5 times net debt to adjusted EBITDA. Capital allocation must weigh brand investment, bolt-on acquisitions, debt reduction and shareholder distributions. An acquisition creates value only when expected returns justify the price and integration risks.
Price, volume and mix
Haleon’s 3.0% organic revenue growth in 2025 comprised 2.3 percentage points of price and 0.7 percentage points of volume and mix. This decomposition matters because raising prices can support revenue in the short term but may constrain demand if consumers face affordability pressure. Volume and mix can reflect category shifts, product innovation and consumer purchasing patterns. A company cannot sustainably rely on price increases alone if competitors offer acceptable alternatives. Haleon’s challenge is to translate product differentiation into both repeat demand and attractive margins. Management should monitor category growth and brand share alongside organic revenue.
Related Haleon analysis: Business Model | Business Strategy | SWOT | PESTEL
Health Inclusivity, Risk and 2026 Outlook
Health inclusivity and sustainability
Haleon’s purpose is to deliver better everyday health with humanity. The 2025 report describes a refreshed health inclusivity and sustainability agenda, alongside a 55% reduction in net Scope 1 and 2 carbon emissions from its 2020 baseline under its reporting definition. Health inclusivity involves making everyday health more accessible and understandable, but social impact should be assessed using specific programme measures. Packaging, manufacturing, ingredient sourcing and product safety also create environmental and compliance responsibilities. Sustainability commitments should be linked to transparent boundaries and measurable outcomes rather than treated as proof that all impacts have been eliminated.
2026 outlook and risks
Haleon’s 2025 Annual Report sets out a 2026 expectation of 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency. These are management expectations, not guaranteed results. Medium-term ambitions include 4% to 6% annual organic revenue growth. Risks include weaker consumer demand, retailer inventory changes, cold and flu incidence, product safety, regulatory requirements, foreign exchange and competition. Investors should track organic versus reported revenue, price versus volume/mix, category market share, operating margins, cash flow and leverage. The business model succeeds when trusted brands generate repeat demand and productivity finances sustainable innovation.
The customer problem
Consumers want accessible solutions for everyday conditions such as tooth sensitivity, pain, coughs, colds and digestive discomfort. Many seek effective self-care without a prescription, but need confidence that claims are scientifically supported and products are safe when used as directed. The consumer healthcare market therefore competes on efficacy, convenience, recommendation, price and familiarity. Haleon’s brands address distinct occasions rather than one uniform need. A toothpaste for sensitivity may be purchased routinely, while cold remedies depend more on seasonal incidence. This diversity helps the portfolio, yet requires different product development, messaging and inventory decisions across categories.
Related Haleon analysis: Business Model | Business Strategy | SWOT | PESTEL
Why brand investment must follow evidence
Haleon spent 20.5% of revenue on advertising and promotion in 2025 and increased adjusted R&D investment. This creates a demanding return-on-investment question. Marketing can expand awareness, but scientific evidence and product experience determine whether health claims translate into repeat purchases. The company should prioritise products where consumers perceive a meaningful benefit and where retailers see sustained demand. Brand-building budgets need category-specific measurement rather than uniform spending rules. Productivity gains can finance investment, but managers must avoid increasing advertising merely because savings are available.
The importance of execution in North America
North American organic revenue declined 0.4% in 2025, while other major regions grew. Management should assess retailer inventory, promotional effectiveness, product availability and consumer affordability before assuming the problem is solely cyclical. Improved category execution may require different pack sizes, innovation, channel strategies or commercial terms. The objective is not to maximise shipments into retailers at year-end, but to strengthen consumer sell-through and profitable repeat purchasing. North America is a reminder that a global portfolio of recognised brands still depends on local commercial decisions.
Testing the operating model redesign
The January 2026 operating model announcement aims to increase agility and improve marketing and brand-building capabilities. Organisational changes can shorten decisions and clarify accountability, but transition can distract teams and create temporary costs. Success should be measured through speed to market, category share, productivity, employee capability and profit conversion. New reporting lines are not evidence of better performance by themselves. Haleon’s medium-term ambitions require the redesign to support both innovation and operational discipline.